Microsoft used to brag about the fact that Deliotte was using Office365. I guess that will stop.
Deliotte likely didn’t want to pay for the complete (expensive) o365 licence. As a result no 2 step verification from Microsoft. I read that in the UK they had 2SV. However the main admin account on O365 remained unprotected by 2sv.
I guess that is one the reasons that I like G Suite for enterprises. Google takes security seriously. They give everyone 2sv for free in their licence. Google gives partners a fee to give security workshops to customers to explain how to apply security measurements.
The Union Association survived for only one season (1884), as did the Players' League (1890), an attempt to return to the National Association structure of a league controlled by the players themselves. Both leagues are considered major leagues by many baseball researchers because of the perceived high caliber of play and the number of star players featured. However, some researchers have disputed the major league status of the Union Association, pointing out that franchises came and went and contending that the St. Louis club, which was deliberately "stacked" by the league's president (who owned that club), was the only club that was anywhere close to major league caliber.
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding the potential of ibrutinib and its further development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges inherent in product research and development, including the uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products or new indications; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.